Literature DB >> 30385176

A-kinase anchor protein 12 (AKAP12) inhibits cell migration in breast cancer.

Regina You Zhen Soh1, Jia Pei Lim2, Ramar Perumal Samy1, Pei Jou Chua3, Boon Huat Bay4.   

Abstract

A-kinase anchor protein 12 (AKAP12) also known as Gravin and SSeCKS, is a novel potent scaffold protein for many key signaling factors, such as protein kinase C (PKC), PKA, cyclins as well as F-actin. AKAP12 expression is known to be suppressed in several human malignancies including breast, prostate, gastric and colon cancers. In this study, we evaluated the role of AKAP12 in the migration of breast cancer cells, an important cellular process in cancer progression. AKAP12 gene expression was analyzed in human breast cancer tissues using the Gene expression-based Outcome for Breast cancer Online (GOBO) database and TissueScan array, followed by relapse free survival (RFS) analysis with the Kaplan-Meier Plotter. AKAP12 protein was then analyzed in normal MCF10A breast cell line and six different breast cancer cell lines (AU565, Hs578T, MCF7, MDA-MB-231, T47D and ZR751). After which, siRNA-mediated knockdown of AKAP12 was carried out in MCF10A, MDA-MB-231 and Hs578T cells, followed by phenotypic assays. AKAP12 was observed to be reduced in breast cancer tissues as analyzed by GOBO and TissueScan array. Kaplan Meier survival analysis revealed that patients with AKAP12 gene expression had a higher RFS survival. There was also decreased AKAP12 protein expression in breast cancer cell lines compared to MCF10A normal epithelial breast cell line. Knockdown of AKAP12 in both MCF10A cells and Hs578T cells induced cell migration but did not alter cell proliferation. Moreover, siAKAP12 in aggressive MDA-MB-231 breast cancer cells led to an increase in cell migration. Immunofluorescence analysis of AKAP12 depleted MCF10A cells also revealed formation of thick stress fibers which could affect cell migration. Hence, the findings in this study suggest that AKAP12 is a potential metastasis suppressor in breast cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  A-kinase anchor protein 12 (AKAP12); Breast cancer; Cell migration; Tumor suppressor

Mesh:

Substances:

Year:  2018        PMID: 30385176     DOI: 10.1016/j.yexmp.2018.10.010

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  8 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  AKAP12 ameliorates liver injury via targeting PI3K/AKT/PCSK6 pathway.

Authors:  Xuan Wu; Yuhong Luo; Shan Wang; Yueying Li; Meiyu Bao; Yuanjiang Shang; Lei Chen; Weiwei Liu
Journal:  Redox Biol       Date:  2022-05-06       Impact factor: 10.787

3.  LINC00163 inhibits the invasion and metastasis of gastric cancer cells as a ceRNA by sponging miR-183 to regulate the expression of AKAP12.

Authors:  Jun Zhang; Hai-Yan Piao; Shuai Guo; Yue Wang; Tao Zhang; Zhi-Chao Zheng; Yan Zhao
Journal:  Int J Clin Oncol       Date:  2020-01-01       Impact factor: 3.402

4.  Upregulated PPARG2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer.

Authors:  Feng Li; Tingting Lu; Dongmei Liu; Chong Zhang; Yonghui Zhang; Fulu Dong
Journal:  Cell Death Dis       Date:  2021-05-22       Impact factor: 8.469

Review 5.  Molecular Mechanism and Approach in Progression of Meningioma.

Authors:  Zhiwei Shao; Lihong Liu; Yanghao Zheng; Sheng Tu; Yuanbo Pan; Sheng Yan; Qichun Wei; Anwen Shao; Jianmin Zhang
Journal:  Front Oncol       Date:  2020-09-11       Impact factor: 6.244

6.  Comprehensive Analysis of the Immune Implication of AKAP12 in Stomach Adenocarcinoma.

Authors:  Zhiquan Xu; Ling Xiang; Linglong Peng; Haitao Gu; Yaxu Wang
Journal:  Comput Math Methods Med       Date:  2022-09-13       Impact factor: 2.809

7.  Pan-cancer analysis of the prognosis and immunological role of AKAP12: A potential biomarker for resistance to anti-VEGF inhibitors.

Authors:  Qiuju Liang; Jinwu Peng; Zhijie Xu; Zhilan Li; Feng Jiang; Lingzi Ouyang; Shangjun Wu; Chencheng Fu; Ying Liu; Yuanhong Liu; Yuanliang Yan
Journal:  Front Genet       Date:  2022-08-30       Impact factor: 4.772

8.  From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity.

Authors:  Darja Kanduc; Yehuda Shoenfeld
Journal:  Glob Med Genet       Date:  2020-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.